Trial Profile

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 05 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Apr 2025 According to Regeneron Pharmaceuticals media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
18 Oct 2024 According to a Regeneron Pharmaceuticals media release, the three-year data from the PHOTON trial for EYLEA HD in DME were previously presented at the American Academy of Ophthalmology annual meeting.
18 Oct 2024 Results presented in the Regeneron Pharmaceuticals Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com